Tonogenchoncel-L

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameTonogenchoncel-L
Drug Alias NameTissueGene-C(S)TGF-beta-1 gene therapyTransforming growth factor-beta-1 gene therapy,TissueGene-CInvossa-KInvossa +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Cartilage cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActionTransforming growth factor beta 1 modulators
TargetsTransforming growth factor beta 1
Therapy Area/IndicationsOsteoarthritis, KneeOsteoarthritisIntervertebral Disc Degeneration
Global Approved IndicationsOsteoarthritis
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2017/07/01
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTissuegene
China Registration ClassN/A

Develop Information

Active CompaniesJuniper Biologics Pte LtdKolon Tissuegene IncKolon Life Science. Inc
Inactive CompaniesN/A
Active IndicationsOsteoarthritisIntervertebral Disc Degeneration
Inactive IndicationsOsteoarthritis, Knee

Other Information

ATC CodeV03AX
Related LinksN/A